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An Introduction to this Issue
Paulami Naik and Bonnie Marshall
Alliance for the Prudent Use of Antibiotics
A healthy human intestinal tract hosts 10 times as
many bacteria, as there are cells in the human body.
Represented in this population are 400 to 1000
bacterial species distributed among nine phyla. [1,2]
These bacteria provide us with energy through
fermentation, produce vitamins for our needs, protect us
from infection, and ensure proper functioning of our
immune system. [3] The specific distribution of bacteria
that colonizes our gut at any given time can have an
important effect on our health and it can be manipulated
with the use of ―probiotics‖ and ―prebiotics‖.
Probiotics are "live micro-organisms that confer a
health benefit on the host when consumed in adequate
amounts." [4] The most commonly used and best studied
probiotics are
species of the bacteria Lactobacillus,
Bifidobacteria, and Streptococcus and the
yeast Saccharomyces boulardii-—typically delivered
singularly or in combination via various yogurt
preparations, or as supplemental capsules. Less
frequently, whole fecal transplants from healthy donors
are utilized as suppositories. Often discussed in relation
to probiotics are non-live ―prebiotics‖. Prebiotics are
―nondigestible food ingredients that beneficially affect
the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the
colon, and thus improve host health.‖ [5] In this issue of
the APUA Clinical Newsletter, we focus solely on
probiotics.
The first formal research on probiotics dates back to
the early 1900s. In 1907, Russian Nobel laureate, Dr. Elie
Metchnikoff published The Prolongation of Life in which
he noted that exceptionally long-lived Bulgarian
peasants, consumed large quantities of sour milk
containing Lactobacillus bulgaricus. He wrote, ―The
dependence of the intestinal microbes on the food makes
it possible to adopt measures to modify the flora in our

bodies and to replace the harmful microbes by useful
microbes." [6] Through this work he established a
foundation for the study of probiotics.
With the advent of antibiotics, the interest in
probiotics lay largely dormant for several decades.
However, with the resurgence of interest in the gut flora,
the previous 15 years have witnessed significant
advances in the characterization of select gut probiotic
strains and on substantiation of their health claims.
Current investigations into the human microbiome, such
as the work of the National Institute of Health‘s Human
Microbiome Project, are revealing the complexity of the
organisms inhabiting the human body. Dr. Martin Blaser,
professor of microbiology at New York University, and
investigator of the link between gut flora and obesity
states, ―We‘re still learning how far the impact of the
microbiome reaches and the costs of perturbing it.‖ [7]
The interest in the micro biome has advanced the
probiotic field as individual strains and functions are
being researched. Nonetheless we are still on the frontiers
of understanding their specific roles and potential uses.
Molecular and genetic studies are making significant
advances in understanding the mechanistic basis
underlying the benefits s of probiotic strains.
Relation to Antibiotic Resistance
Continued or excessive use of antibiotics is known to
disrupt the normal micro biota of the human body.
Promptly restoring normal balance of flora following
treatment is important for preventing unrestrained
overgrowth of undesirable, multidrug resistant strains
such as Clostridium difficult and other hospital acquired
opportunists. Probiotics have emerged as a valuable
adjunct to antibiotic therapy and as a useful tool in
avoiding or reducing antibiotic use. Given the recent
decline in the development of new classes of antibiotics
and the increase in multi-drug resistant superbugs, the
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search for additional approaches for treatment and
prevention of bacterial disease is increasingly urgent.
Probiotic Use and Safety
Probiotics are widely considered to be safe for human
oral and vaginal use and there is a long history of the use
of fermented milk products with minimal recorded
reported side effects. The number of probiotic products
available on the world market is estimated to be over
2000 [8], but the industry remains largely unregulated
and unstandardized—making comparative studies
difficult. To begin filling this void, scientists have
formalized groups such as the International Scientific
Association for Probiotics and Prebiotics (ISAPP), a nonprofit founded in 2002 to raise the scientific credibility of
the field by working with experts and conducting
meetings on high quality research. By providing an
objective, science-based voice, ISAPP hopes to benefit
the end users of these products by helping them make
informed choices. [9] ISAPP has endorsed the guidelines
set by the World Health Organization (WHO) and the
United Nations Food and Agriculture Organization
(FAO) for evaluation of probiotics—governing, strain
designation, efficacy/effectiveness and safety. [4,10] For
example, new strains and products should be proven safe
in human studies amend those bearing some limitations,
(such as use of S. boulardii [S. cerevisiae]) in patients
with a leaky gut or other risks) should be clearly labeled.
[11]
In the United States, probiotics are currently classified
as ―dietary supplements‖, (not ―drugs‖) and as such, the
Food and Drug Administration (FDA) only requires
premarket notiﬁcation, with no demonstrations of safety
and efficacy required. [12] Due to their overall safety,
guidelines for use of probiotics in the hospital are
generally lacking, although some caution is advised for
use in certain disease states (e.g., severe colitis, bowel
leaks, neutropenia) where the potential exists for the
probiotic to enter the blood or peritoneum. [13] Likewise,
special care should be taken by healthcare personnel who
handle both probiotic capsules and venous catheters in
order to avoid transfer to the bloodstream. [12] Of more
recent interest and concern are safety considerations
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relating to transferable genetic elements that may confer
antibiotic resistance from the probiotic to pathogenic
strains, or even to the commensal flora. [14]
Current Applications and Future directions
To date, only a very few probiotic strains are well
researched and tested and most relate to interventions in
diarrheal illness. Confounding factors in clinical trials
have undermined and limited the ability to clearly
determine efficacy for other strains and infectious disease
states. Fewer supporting studies exist in the area of
respiratory disease, but probiotics may offer some
promise in treating sinusitis, bronchitis, and pneumonia.
The current lack of rapid diagnostics for upper
respiratory illness (URI) has led to considerable overuse
of antibiotics in this area and there is a large potential for
probiotic intervention. A recent Cochrane meta-analysis
of 10 clinical trials concluded that probiotic intervention
exceeded the placebo in reducing episodes of acute URI,
with some more limited evidence that probiotics could
reduce the prescription of antibiotics. [15]
In this issue of the APUA Newsletter, current as well
as future probiotic applications are examined. Tufts
University Schools of Nutrition and of Medicine are at
the forefront of probiotics research and some of their
experts have contributed articles to this issue. Drs. Barry
Goldin and Sherwood Gorbach, co-discoverers of
Lactobacillus GG–the first probiotic proven to colonize
the gastrointestinal tract—offer an overview of the
current and proposed uses of probiotics and evaluate the
strength of supporting evidence. Dr. Shira Doron reviews
the use of probiotics for prevention and treatment of
gastrointestinal diseases. Interesting perspectives from
research in developing countries are provided by Dr.
Gregor Reid of Western University in Canada and Drs.
Christine Wanke and Honorine Ward of Tufts Medical
School, who examine probiotics as useful interventions in
the vicious cycle of malnutrition and infectious disease
that severely undermines childhood development.
In their recognition and endorsement of probiotic
therapy, the United Nations and World Health
Organization, issued the call for ―Efforts…to make
probiotic products more widely available, especially for
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relief work and populations at high risk of morbidity and
mortality‖. This call has yet to be ratified by government
agencies and multinational probiotic companies. With the
looming global crisis in antibiotic resistance, and a dearth
of new antibiotics in the pipeline, there persists a critical
need for adjuncts and alternatives to antibiotic therapy
that will aid in preserving our severely compromised
antibiotic treasures. With their prospects of enhancing
antibiotic efficacy, alleviating antibiotic side effects, and
even reducing or eliminating the need for antibiotics,
coupled with low cost and relative accessibility,
probiotics offer promise in filling this void, but clearly,
better designed, more rigorous studies are needed to
optimize their full potential as interventions, with or
without antibiotic therapy.
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Clinical Indications for Probiotics: An
Overview
The following article was extracted with permission from a publication of the same title which originally
appeared in Clin Infect Dis. 2008. 46 (l 2): S96-S100. This reprint has been updated with new references
(see Refs 45-48.)

Barry. R. Goldin, Ph.D. and Sherwood. L. Gorbach, M.D.
Tufts University School of Medicine, Boston, Massachusetts

Probiotics have been defined as ―live microorganisms
which when administered in adequate amounts confer a
health benefit on the host‖. [1] Probiotics have been used
to treat a wide range of diseases, ailments, and conditions
that affect humans and animals. Additional medical
applications have been proposed for potential future uses,
depending on the outcomes of future experimental
studies. The clinical uses of probiotics are broad;

however, the clinical indications based on evidence-based
studies are much narrower and are open to continuing
evaluation. Table 1 contains a partial list of human
diseases and conditions that probiotics have been used to
prevent and/or treat.
The current and proposed uses of probiotics cover a
wide range of diseases and ailments. An attempt has been
made to classify the quality of evidence that supports
these various applications. [44] These classifications
Table 1. Medical applications in humans
are based on existing studies, most of which are cited
for different classes of probiotics.
in this article, and not on an exhaustive review of the
Medical condition
Class(es) of
References entire literature on probiotics. The broad classifications
include (Table 2) applications with proven benefits,
probiotic
applications with substantial evidence that require
Lactose maldigestion
LAB and
[2-5]
Streptococcus
additional support, promising applications that need
Salivarus subsp.
substantial additional evidence, and proposed future
thermophilus
applications.
Gastroenteritis
Proven benefits of probiotics include the treatment of
Acute diarrhea
LAB, Bifidobacterium [6-17]
acute and antibiotic-associated diarrhea; applications
species or
with substantial evidence include the prevention of
Saccharomyces
boulardii
atopic eczema and traveler's diarrhea; promising
Antibiotic-associated diarrhea LAB or S. boulardii
[18-24]
applications include the prevention of respiratory
infections in children, prevention of dental caries,
Traveler’s diarrhea
LAB
[25,26]
elimination of nasal pathogen carriage, prevention of
Allergies
LAB
[27-31]
relapsing C. difficile–induced gastroenteritis, and
Clostridium difficile-induced colitis LAB
[32-34]
treatment of inflammatory bowel disease; and
Dental caries
LAB
[35]
proposed future applications include the treatment of
Intestinal inflammation in children LAB
[36]
rheumatoid arthritis, treatment of irritable bowel
with cystic fibrosis
syndrome, cancer prevention, prevention of ethanolRespiratory infection in children
LAB
[37]
induced liver disease, treatment of diabetes, and
Nasal colonization with pathogens LAB
[38]
prevention or treatment of graft-versus-host disease.
Inflammatory bowel disease or
LAB
[39-43]
The use of probiotics in medical practice is rapidly
irritable bowel syndrome
increasing, as are studies that demonstrate the efficacy
NOTE. LAB, lactic acid bacteria
of probiotics. A note of caution should be applied:
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Table 2. Present and future clinical
applications of probiotics, by level
of evidence of efficacy
Applications with strong evidence
Gastroenteritis
Acute
Antibiotic associated
Applications with substantial evidence of efficacy
Allergic reactions, specifically atopic dermatitis
Applications that have shown promise
Childhood respiratory infection
Dental caries
Nasal pathogens
Relapsing Clostridium difficile-induced
gastroenteritis (prevention)
Inflammatory bowel disease
Potential future applications
Rheumatoid arthritis
Irritable bowel syndrome
Cancer (prevention)
Ethanol-induced liver disease
Diabetes
Graft-versus-host disease
negative findings are being reported, as would be
expected as more studies are being performed and as
more applications are being sought for the use of
probiotics.
Overall, probiotics appear to be here to stay as part of
the physician's armamentarium for the prevention and
treatment of disease; however, more evidence-based
research is required to firmly establish medical areas of
use and areas in which probiotics are not applicable.
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Probiotics for the Treatment and
Prevention of Gastrointestinal Disease
Shira Doron, M.D.
Attending Physician, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center
Assistant Professor of Medicine, Tufts University School of Medicine

Gut bacteria
The bacteria in our gastrointestinal tract have an
important effect on our health. The intestinal microbiota
can be altered by such interferences as a course of
antibiotics, or an episode of intestinal infection. Aberrant
gut microbiota have been demonstrated not only in
diarrheal diseases, but also in inflammatory bowel
disease, irritable bowel syndrome and even in diseases
which manifest outside the gastrointestinal tract. [1]
Probiotics
Living microorganisms have long been used as
supplements to restore gut health at times of dysfunction.
They do so not only by changing the intestinal
microbiota, but also by their immunomodulatory effects
as well as elaboration of antibacterial substances.
A probiotic is ―a live microbial food ingredient that,
when ingested in sufficient quantities, exerts health
benefits on the consumer‖. [2] To be considered a
probiotic, a bacterial strain must be of human origin and
safe for human use. Genera represented in this category
include lactobacilli, bifidobacteria, streptococci, and
enterococci. There are many probiotic strains, each with
unique characteristics. These have been studied for use
in the treatment and prevention of a wide range of
diseases.
Treatment and prevention of acute diarrhea
Several meta-analyses and systematic reviews have
been written on this topic and have found probiotics to be
effective. [3-7]
Lactobacillus rhamnosus strain GG (LGG) and
Lactobacillus reuteri have been the most commonly

studied probiotics for use in the treatment of acute
diarrhea in children. [7] The largest study of LGG for
acute diarrhea in children was conducted by the European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) in 2000. In this study, 287
children in ten countries ages 1 to 36 months admitted
with moderate to severe diarrhea were randomized to
receive either LGG or placebo along with standard oral
rehydration solution. The patients who received LGG
had a shorter duration and decreased severity of illness,
had a shorter hospital stay and were less likely to have
persistent diarrhea. [8]
Shornikova et al performed two smaller studies, one
randomizing 86 children and one randomizing 40
children ages 6 to 36 months to Lactobacillus reuteri or
placebo. The duration of watery diarrhea was decreased
in the treated group, as was the percent of subjects with
persistent diarrhea on day two of illness and the
frequency of diarrhea on day two. Colonization of the
intestine by Lactobacillus reuteri was confirmed by stool
culture. The larger study, which had higher and lower
dose arms, also showed a correlation between the dosage
of L. reuteri and the clinical effect. [9,10]
Prevention of antibiotic-associated diarrhea and
gastrointestinal side effects
Antibiotic-associated diarrhea (AAD) is diarrhea that
occurs during or shortly after administration of an
antibiotic, with no other known cause. The frequency of
occurrence varies with the antibiotic, but is estimated to
occur in approximately 25% of the patients receiving
antibiotics. The rate of AAD in children may be less, as
little as 11% in one study, where it was found to be
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highest (18%) in children under the age of two years. [11]
McFarland conducted the largest meta-analysis to date
evaluating 25 randomized controlled trials of probiotics
for the prevention of AAD including 2810 subjects. [12]
Of these, 13 (52%) demonstrated a significant reduction
in the incidence of AAD in the probiotic-treated group
compared with the placebo group. Among the studies on
adults, only 44% had a reduction in AAD in the probiotic
group, while 67% of the pediatric studies reported a
benefit in the probiotic group. Many different probiotic
strains were used in these trials, including several
probiotic mixtures, and at various doses. When these
analyses were stratified by probiotic strain, only
Lactobacillus rhamnosus GG,
Saccharomyces boulardii and the
various probiotic mixtures had
“Given the current
significant efficacy.
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H. pylori as well as its binding capacity to human
mucosecreting cells in vitro. Probiotics have also been
shown to inhibit urease activity of H. pylori both in vitro
and in the mouse stomach. [15] Human studies have
demonstrated various effects of probiotics on H. pylori
infection. Studies have shown a decrease in urea breath
test values after treatment with probiotics. [20-23] Wang
et al showed reduced H. pylori density and gastritis
severity in antral biopsies. [20]

More recent studies have focused on probiotics
as adjunctive therapy to improve the rate of H. pylori
eradication with standard multi-drug therapy. Sykora et
al studied 86 symptomatic H. pylori-positive children
who were randomized to
omeprazole, amoxicillin and
clarithromycin plus or minus
state of antimicrobial fermented milk containing
resistance and stagnating antimicrobial Lactobacillus casei DN-114
Prevention of travelers’ diarrhea
drug development, it is critical to look to 001. There was a significantly
Diarrhea occurs in 30% to 50%
or more of travelers to developing
antibiotic alternatives such as probiotics enhanced therapeutic benefit
with the addition of the
countries. [13] There have been a
to treat and prevent infections.”
probiotic from 61% to 92%.
number of studies on the use of
[24] Sheu et al studied 138
probiotics for the prevention of
adults who had failed standard
travelers‘ diarrhea and the results
triple-drug therapy for H. pylori, randomizing them to pre
are conflicting. The largest was a Finnish study that
-treatment for four weeks with yogurt containing
randomized 756 subjects traveling to two resorts in
Lactobacillus acidophilus La5, Lactobacillus bulgaricus,
Turkey to take Lactobacillus GG or placebo during their
and Bifidobacterium lactis Bb12 or no pre-treatment
stay abroad. The results from subjects at one of the
followed by quadruple therapy with omeprazole,
resorts were not statistically different between groups,
amoxicillin, metronidazole and bismuth subcitrate. There
while at the other resort, the LGG group had a
was a significantly higher eradication rate in the prestatistically significant protection rate of 39.5% in the
treated group (86% versus 71%). [25] On the other hand,
first week and 27.9% in the second week. [14]
in a study of 65 children who tested positive for H. pylori
Helicobacter pylori infection
in Argentina treated with standard triple therapy followed
Helicobacter pylori is responsible for such conditions
by three months of yogurt (with Lactobacillus casei and
as gastritis, peptic ulcers, and gastric cancer. It colonizes
Bifidobacterium animalis) or milk placebo, no
the epithelial cells of the stomach and is capable of
differences were seen in the eradication rates at one and
penetrating these cells. In vitro studies have demonstrated
three months. [26]
that various strains of Lactobacillus have antibacterial
Treatment and prevention of Clostridium difficile
activity against H. pylori [15, 16] and animal studies have
Clostridium difficile infection can cause a spectrum of
shown their ability to prevent Helicobacter infection and
disease ranging from subclinical infection to severe
colonization [15, 17-19] and to attenuate gastritis. [19]
disease including profuse diarrhea, colitis, toxic
Lactobacillus acidophilus decreases the viability of
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megacolon and death. The disease generally responds to
therapy with antibiotics but recurrences are common and
develop in up to one third of patients. These recurrences
can be refractory to therapy. Dendukuri et al conducted a
systematic review on the use of probiotics for prevention
and treatment of C. difficile-associated diarrhea (CDAD)
in adults. [27] Four randomized controlled studies were
identified with CDAD as the primary outcome. Four
additional randomized controlled studies identified
CDAD as a secondary outcome. Strains studied included
S. boulardii in 5 of the studies, and different strains of
Lactobacillus in the other three, one in combination with
Bifidobacterium. In these studies, probiotics did not have
a significant effect on the prevention of CDAD, and only
two studies showed a benefit for probiotics in treatment
of CDAD, particularly in patients with more severe
disease, however the variability in the use of concomitant
antibiotics against C.difficile make interpretation of the
results difficult.
In conclusion, there is considerable need for many
more well designed trials to be conducted before we can
fully understand the benefits of probiotics in the
treatment and prevention of gastrointestinal diseases.
Each strain must be studied individually for its efficacy in
each disease state, since results from the study of one
strain cannot be extrapolated to another. Given the
current state of antimicrobial resistance and stagnating
antimicrobial drug development, it is critical to look to
antibiotic alternatives such as probiotics to treat and
prevent infections.
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Develping Country Perspective:
Probiotics With or Without Antibiotics
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When I read an article on the BBC online news on
November 19th, 2004 stating that the World Health
Organization and Unicef was recommending daily use of
trimethoprim-sulfamethoxazole for every HIV-positive
child in Africa, I somewhat despaired at society's
approach to disease management. It had been 13 years
since we had shown that 7 days of antibiotic therapy
could disrupt the beneficial vaginal microbiota for over
six weeks [1], and nine and a half years since the British
Parliament debated the deaths, injuries and other sideeffects of trimethoprim-sulfamethoxazole. While this
combination is effective at treating many infections, the
thought that two respected organizations were advocating
40 billion doses to children per year seemed madness.
Given Martin Blaser's recent Nature article highlighting
the folly of overuse of antibiotics and the critical
importance of the host's beneficial microbes [2], my
advocacy of alternative approaches seems justified.
In hindsight it is ironic that in the same year, 2004, we
launched a program in Tanzania whereby local mothers
('mamas') would produce a yogurt supplemented with
probiotic Lactobacillus rhamnosus GR-1, with the aim of
improving the quality of life of HIV-positive children and
adults (Figure 1). [3] The yogurt contains about 9 g of
protein per serving yielding >15% of the recommended
daily allowance and 8 g of fat per serving. It is a rich
source of many micronutrients, including zinc,
phosphorous, calcium (33% of daily recommendation),
pantothenic acid, vitamin B12 (>40% of daily
recommendation), riboflavin and vitamin A (10% of
daily recommendation). [4] Such is the enthusiasm for
the program, that the communities have helped set up
another 11 kitchens in Tanzania and Kenya with more
planned there and in Rwanda, Burundi and Malawi. To

date, these have employed over 60 mamas and farmers,
been host to 55 student interns from Western University
in Canada, and led to 26 publications on various aspects
of the project. In addition, over 20,000 students at
Western have been engaged in fund raising and
dissemination of the project.
Whilst such engagement in Africa is laudable, are
there health benefits associated with the yogurt intake?
Answering this required setting up research
collaborations with various partners, in particular the
National Institute for Medical Research in Mwanza, and
performing studies with essentially no funding from
Canadian government granting agencies. Nevertheless,
interesting findings have emerged with administration of
yogurt and capsules containing L. rhamnosus GR-1 and
Lactobacillus reuteri RC-14.
The first study followed 49 male and female adults
(age 35–45), with 29 receiving the probiotic yogurt (250
mL daily for 30 days) and 20 not. Five in each group
were taking anti-retroviral therapy (ART). Compliance
was good, but on average, participants still missed 3–5
days yogurt, due to being too sick to travel, lacking a
family member to assist with program adherence, or fear
of domestic violence against women who were leaving
the home to get yogurt. Almost all of the participants had
marked improvements in their weight, and eight showed
an improvement in their weight category, moving from
severely to moderately underweight or from moderately
underweight to mildly underweight. Significant increases
were noted in thiamin, riboflavin, biotin, vitamin C,
pantothenic acid, calcium (p <0.0001), copper,
phosphorus and potassium. Based upon self-perceptions
and physician diagnoses, consumers of the probiotic
yogurt had significantly fewer fungal conditions over the
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time period of 60 days [r = 0.417, n = 49, p < 0.01],
fewer episodes of diarrhea [r = 0.372, n = 49, p < 0.01],
and substantially lower degree of fatigue [r = −0.365, n =
49, p < 0.01]. This was the first evidence that the yogurt
might act as a prophylactic against infection.
The finding has been further supported by an
observational study. [5] In addition, the prophylactic
effect in reducing urinary tract infection (UTI)
recurrences has been confirmed with strains GR-1 and
RC-14 in capsules administered to elderly Dutch women
for one year [6], and with Lactobacillus acidophilus
given to South Korean children with vesicoureteral reflux
[7], both compared to trimethoprim-sulfamethoxazole. Of
importance, the GR-1/RC-14 treatment resulted in no
drug resistance changes compared to the antibiotic treated
group in whom resistance to trimethoprimsulfamethoxazole, trimethoprim, and amoxicillin
increased within only one month from 20%-40% to 80%
-95% in E. coli from the feces and urine. [6] Likewise, in
the study of children, sensitivity of E. coli to
trimethoprim-sulfamethoxazole was 57.1% in the
probiotic group and reported as zero in the antibiotic
group (P<0.019). [7] Such results clearly indicate the
flaw in the WHO/Unicef approach and the need to retain
antibiotics for curing infection rather than preventing
them. Moreover, the findings indicate that probiotics
need to be included in discussions on how to prevent
infant deaths from HIV in Africa. Rather than forcing
African children to take a developed world antibiotic
every day resulting in that agent no longer being able to
cure infection because of resistance, would it not make
more sense to create locally driven initiatives that take
advantage of available food sources, stimulate selfempowerment and deliver fairly similar disease
prevention?
The advantages can potentially extend beyond
preventing infection. One study of 40 patients showed
superior cure of bacterial vaginosis (BV) with
intravaginal probiotics versus metronidazole. [8] Studies
in Nigeria and Brazil have shown that combining
Lactobacillus GR-1 and RC-14 with antimicrobials can
improve cure of vaginal infections. [9-12] The effect
appears to involve creating an environment that restores
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the indigenous lactobacilli as the dominant organisms,
while in the case of Candida, suppressing fungal growth,
increasing expression of stress-related genes, lowering
expression of genes involved in fluconazole resistance
[13] and up-regulating IL-8 and IP-10 secretion. [14]
This is a good example of using beneficial organisms to
counter pathogenic ones. Other examples of this
phenomenon have been published. [15,16]
A clinical study using Lactobacillus crispatus CTV05 administered intravaginally following metronidazole
therapy, showed that an ability of the organism to persist
on the mucosa was associated with significant reduction
in BV pathogens, Gardnerella and Atopobium. [17] In a
randomized, placebo-controlled trial study of HIVpositive children, daily use of formula containing
Bifidobacterium bifidum with Streptococcus
thermophilus increased the mean CD4 count (+118 cells
mm(-3)) compared to -42 cells mm(-3) for children
receiving control formula (p = 0.049) (791 cells mm(3)). [18]
In summary, the current medical approach to
managing infection remains too focused on traditional
antimicrobial agents and protocols, disregarding their
side effects and increased resistance. New agents are long
overdue for conditions such as UTI and BV and for
patients with chronic diarrhea. Probiotics certainly
warrant consideration to manage infections and

Figure 1. The Tukwamuane Women's Group whose Mabatini kitchen
in Mwanza, launched the Western Heads East probiotic yogurt
initiative, with production beginning in January 2005.
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potentially also improve antimicrobial efficacy. The
social business model used in Africa should be
considered in the so-called developed world, where
poverty, access to adequate care, and poor nutrition all
contribute to infections continuing to cause widespread
morbidity and mortality. The success obtained from fecal
transplant in curing Clostridium difficile caused mostly
by antibiotic eradication of the gut microbiota [19],
suggests that the types of probiotics that will be used in
the future will be different in form and delivery from the
present. Such a change needs to be aligned with major
alterations to how probiotics are regulated, and in
creation of a system understood by lay people as well as
policy makers. [20] With few side effects and excellent
patient compliance, HIV positive patients are asking why
are more foods not targeted to reduce the burden of
disease? [21]
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The vicious cycle of infectious diarrheal disease and
malnutrition is responsible for significant morbidity and
mortality in children under the age of five years,
particularly those from low and middle-income countries.
A recent analysis of child mortality in 2010, estimated
that worldwide about 60% of the 6.7 million deaths that
occur in children under the age of five years are caused
by infectious diseases and that about 10% are due to
diarrhea. [1, WHO] Malnutrition is estimated to
contribute to over one third of child deaths. In 2010,
about 20 million children worldwide were estimated to
suffer from severe acute malnutrition, 171 million
children below five years of age were stunted, and 104
million were underweight. [WHO]
While malnutrition may occur throughout the
childhood years, it may be presumed that loss of weight
or inability to grow may have more of an impact the
earlier it occurs. Such early malnutrition may be referred
to as growth faltering. There is no clear definition of
growth faltering, but it is widely assumed to begin around
the time of weaning in low and middle income countries
and is generally assessed by weight-for-age (WAZ),
height-(or length)-for age (HAZ) and weight-for-height
(WHZ) Z scores. [WHO] An analysis of the WHO
Global Database on child growth and malnutrition of 39
nationally representative data sets from recent growth
monitoring programs in developing countries [2] found
the following: For children in the developing world at
birth, in comparison to the National Center for Health
Statistics (NCHS), the average weight-for-age, length-for
-age, and weight-for-length are quite close to the

reference. Growth faltering then occurs, so that by 18
months, mean weight-for-age values and mean length-for
-age values are between 1 and 2 standard deviations
below the reference median value.
The three primary growth parameters (WAZ, HAZ,
WHZ) show different patterns. Mean weight starts to
falter about 3 months of age, and declines rapidly until 12
months. Between 12 and 19 months this decline slows.
Most wasting (assessed by WAZ score) in children
occurs in the period between 3 to 15 months of age. For
length, although the mean birth values are close to the
NCHS standard, faltering starts soon after birth and lasts
well into the third year, and is not recovered thereafter.
These processes appear to be independent of each other
and the pattern is remarkably similar in multiple
developing countries.
Current recommendations are that weaning occurs
from 4-6 months onward, as foods other than breast milk
are introduced into the diet. [3, 4] Initiation too early
displaces breast milk, decreases mother‘s milk production
and results in malnutrition, while weaning too late leads
to growth faltering and depressed immune function.
Regardless of the timing, in situations where
environmental contamination is high, weaning exposes
the infant to high levels of enteric pathogens and
increased morbidity and mortality secondary to infectious
disease and malnutrition. Multiple studies from
developing countries have shown that diarrheal disease
significantly increases at about 6 months of age,
secondary to increased exposure of the infant to
pathogens as a result of weaning initiation. [3-6]
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Contamination of water is common and this water is used
in preparation of weaning foods. Contamination of foods
after cooking also occurs.
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adults with relapsing diarrhea [28, 29, 50-52]. Likewise,
it has been used to prevent diarrhea. A study of the
ability of LGG to reduce diarrhea in undernourished
Peruvian children suggests that there were fewer episodes
of diarrhea in the children who received the probiotic.
[55] Additionally, LGG has also been shown to enhance
the immunogenicity of oral vaccines. [30]

A malnourished child or a child who is frequently
exposed to enteric pathogens is at higher risk of
developing diarrheal disease. [7-11] Recent studies
suggest that acute watery diarrhea accounts for perhaps
one third of all deaths from diarrhea and dysentery for
Other studies of LGG suggest that it permits healing
another 20%. Persistent diarrhea (PD) is the greatest
of the intestinal mucosa by reducing gut permeability and
problem, accounting for approximately 45% of childhood
by enhancing local intestinal immune responses as well
deaths from diarrhea. [5, 12, 13] A malnourished child is
as by reconstituting the intestinal flora. [31-33] Although
at increased risk for an episode of acute diarrheal disease
the effect of LGG on growth faltering and malnutrition
to become prolonged. [14] In spite of the fact that only 10
has not been extensively studied, the beneficial impact of
-16% of episodes of acute diarrhea progress to PD, the
LGG on intestinal integrity and the ability of LGG to
mortality associated with PD is
reduce the total days of diarrhea
disproportionately high. [12, 13]
are the basis for the hypothesis
“Thus,
interventions
such
as
probiotics
Malnourished children with PD
that LGG will reduce the
may
be
most
effective
during
had a higher risk of death from PD
incidence of growth faltering. The
pregnancy
and
the
first
two
years
of
than better-nourished children
microbial communities in the
life,
the
so-called
“first
1000
days”
within the same community. [15]
gastrointestinal tract consist of
and
may
need
to
target
pregnant
There is also evidence that
over 1000 species and outnumber
women
in
addition
to
their
infants.
“
children who develop PD are
human cells tenfold. [34] These
subsequently at risk for more
communities, known as the
episodes of diarrhea than children who have never had an
―microbiota‖ and their collective genomes, the
episode of PD. [13, 16-18]
―microbiome‖, play a major role in maintaining gut
homeostasis, contributing to nutrition and promoting
Probiotics are viable bacteria, which colonize the
resistance to infection by preventing colonization with
intestine and modify the intestinal miroflora and their
pathogens, modulating innate and adaptive immune
metabolic activities with a beneficial effect for the host.
responses, preserving intestinal mucosal integrity,
[19-21] Lactobacillus rhamnosus, strain GG (LGG)
controlling inflammation and contributing to nutritional
(ATCC 53013), is an extensively studied probiotic strain.
status. Perturbation of the intestinal microbiota is
LGG has been used as therapy in several randomized,
associated with impaired nutritional and immune status,
placebo-controlled trials of acute pediatric diarrhea with
increased susceptibility to infection, and adverse clinical
success. [22-25] LGG has been proven successful in
outcomes. Culture-independent and other high
decreasing the duration of childhood diarrheal illnesses
throughput technologies, including next generation
for which the pathogen was not known, in studies done in
sequencing and mass spectrometry, have enabled rapid
the developing world. In Northern Pakistan, LGG was
and accurate characterization of the intestinal
shown to significantly reduce the duration of acute
microbiome, metagenome, metatransciptome and
diarrheal illness in hospitalized children compared to
metabolome in various physiological as well as
those treated with placebo. [26] LGG was able to
pathological states, such as obesity and inflammatory
significantly reduce the duration of acute watery diarrheal
bowel disease.
illnesses in children in Thailand when compared to
placebo. [27] LGG has also been effective in treating
diarrhea caused by C. difficile in children and in elderly

Recently, alterations in the intestinal microbiota and
their metabolic activities have been implicated as playing
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a role in malnutrition as well as in environmental
enteropathy in children in developing countries. [35, 36]
Although further studies need to be done to confirm this
possibility, this finding raises the possibility that in
addition to provision of adequate quantity and quality of
nutrients, restoration of the gut microbiome to a more
―healthy‖ state with the use of tailored probiotics [34, 378] may have a beneficial effect on malnutrition and
growth faltering in children in resource-poor areas.
Stunting in these children occurs very early in life and is
thought to be initiated during pregnancy and intrauterine
growth. Thus, interventions such as probiotics may be
most effective during pregnancy and the first two years of
life, the so-called ―first 1000 days‖ and may need to
target pregnant women in addition to their infants.
Thus far, probiotic approaches have employed single,
or a combination of a few, beneficial bacterial species.
However, the likelihood that multiple microbes are
involved in contributing to the health of the microbiome
and the recent success of ―fecal transplants‖ [39] suggest
that these approaches may need to be customized to
include multiple microbes with defined metabolic
activities for specific disease states.
The use of
―designer‖ probiotics that are engineered to block
deleterious receptor-ligand interactions of pathogenic
organisms with host cells [40] may also be useful to
target enteric infections that contribute to the vicious
cycle of infectious diarrhea and malnutrition.
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Report from the Field:
Antibiotic stewardship in Bulgaria –
achievements and further needs
Emma Keuleyan, M.D., Ph.D.
Medical Institute of the Ministry of the Interior
APUA-Bulgaria Coordinator
Antibiotic Regulation
In Bulgaria, the Ministry of Health (MH) is the main
regulator and the Bulgarian Drug Agency (BDA) is
responsible for drug licensing and control. In order to be
introduced to the market, an antibiotic needs an
application and assessment. This procedure is based upon
EU rules and the license lasts five years. The MH
organizes a Commission to select drugs to be bought and
reimbursed by the National Health Insurance Fund
(NHIF).
One achievement in 2010 was the strengthening of
control by the BDA on over-the-counter sales of
antibiotics through inspections and penalties. But because
the industry perceives Bulgaria‘s market as unattractive,
important antibiotics such as the group of penicillinaseresistant penicillins, colistin, amphotericin B and
nitrofurantoin are lacking. For example, nitrofurantoin is
not licensed in Bulgaria and patients must travel abroad
and buy the drug from Greece or Turkey.
Finally, there is one new option in the 2011due to the
changes in the Law for Drugs for Human Usage. The
hospitals may now apply for antibiotics not available on
Bulgarian market— if they have been licensed in other
EU countries, and if the hospitals can provide data that no
alternatives are available.
Another important issue is the price of antibiotics. It
was found that many drugs imported or produced by
Bulgarian manufacturers are being sold in Bulgaria at
higher prices than in the other countries. This question
was recently considered by the new Minister of Health
and the president of the NHIF.
Antimicrobial Resistance Surveillance
The National Antimicrobial Resistance Surveillance

(ARS) in Bulgaria dates back to 1998. A National
Reference Laboratory on Quality Control in
Microbiology and Antimicrobial Resistance Surveillance
was created at the National Center for Infectious and
Parasitic Diseases. The Laboratory organizes external
laboratory control twice a year and contributes to the
standardization of antimicrobial susceptibility testing.
Microbiology laboratories in Bulgaria mandatorily
participate in the ARS system BulSTAR. Some hospital
laboratories also participate in the European
Antimicrobial Resistance Surveillance Network (EARSNet) project coordinated by the European Centre for
Disease Prevention and Control (ECDC). Many have

Table 1. Hospital antibiotic consumption in
Sofia, Bulgaria
Year

2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011

Alexander’s
University
Hospital1
25
20
23
28
30
27.5
30
37

Medical
Institute,
Ministry of
the Interior2
29.7
45.9
42.8
46.2
51.8
44.5
54.0
26.7
44.1
49.9

Multi-profile
Hospital3

40.2
35.8
41.3
41.9
40.1
36.3

Units: DDD/100-bed-day
1. Indiscriminated use of ceftriaxone (since 2006) represents 99% of the 3rd
generation cephalosporins and accounts for ~50 % of systemic antibiotics.[1]
2. Rank of antibiotic groups, 2010 in DDD/100 bed-day:
penicillins – 11.1, cephalosporins – 17.4 , penems – 0.3, MLS – 4
aminoglycosides – 3.2, fluoroquinolones – 4.0,
glycopeptides – 0.2, imidazoles – 3.0
3. Relative antibiotic group use: penicillins:10-43 %, cephalosporins: 13-42 %,
MLS: 6-8 %, fluoroquinolones: 10-12 %, aminoglycosides: 4-9%, others:1-3 %. [3]
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traditions in ARS: they collect, analyze and interpret Table 2. Antibiotic usage in 2011 in Pediatric
hospital ARS data and periodically publish booklets, with University Hospital, Sofia, Bulgaria [4]
informational and educational content, that serve policyAntibiotics
DDD/100 Antibiotics
DDD/100
makers. [1,2] The most problematic resistant organisms
bed-day
bed-day
in Bulgaria are the ESBL-producing Enterobacteriaceae
Fluoroquinolones
5.3
Carbapenems
0.5
and multidrug-resistant non-fermenters.
Tetracyclines
0.2
Cephalosporins
21.2
MLS
Macrolides
Most of the laboratories that participated in the Lincosamides
Antibiotic Resistance Prevention And Control (ARPAC) Co-trimoxazole
Penicillins
project organized by the European Society of Clinical
with extended spectrum

Antibiotic Consumption

Microbiology and Infectious Diseases (ESCMID),
continue to survey the antibiotic usage. Table 1 and 2
provide an extract from antibiotic use in several hospitals.
In general, antibiotic consumption in Bulgaria remains
high, and is characterized by an increase in the usage of
third generation cephalosporins and fluoroquinolones, the
antimicrobial agents contributing most to the selection of
resistant strains.
Antibiotic Stewardship
Bulgaria was one of the first countries to develop a
National antibiotic policy. In 1999 an expert committee,
along with the Ministry of Health (majority of the
representatives from APUA), started the Program for
Antimicrobial Resistance Surveillance and Rational
Antibiotic policy, approved by the MH in 2001. The
change of government, however, delayed the immediate
introduction of this program: several years later it has
been executed only in part, due to the lack of financial
support.
Today, a hospital‘s antibiotic policies form an integral
element of its accreditation of hospitals. Clinical
microbiologists, as leaders of a multidisciplinary
antibiotic team, are charged with responsibility of the
program. Each hospital has a list of essential antibiotics.
In general, the policy is restrictive. In the Medical
Institute, Ministry of the Interior, there are three levels of
antibiotic prescribing, instituted after discussion with all
clinicians. Each clinical department elaborates its own
clinical guidelines for the use of antibiotics. Several
audits of antibiotic prescriptions have been conducted,
which has contributed to the amelioration of antibiotic
usage. Annual Reports from the Clinical Microbiology
laboratory about ARS and antibiotic consumption are

with anti-pseudomonas
activity and βlactamase inhibitor

6.3
5.8
0.5
0.8
8.5
2

1st generation
2nd generation
3rd generation
4th generation
Aminoglycosides
Imidazoles

10.8
0.2
10.0
0.2
2.9
4.1

6

being presented and discussed at hospital Medical
Council. Despite these activities, and every-day
consultations, the results are suboptimal. One reason is
the epidemiologic situation in the country. Furthermore,
rational antibiotic therapy necessitates the optimal dosage
regimen of the most effective antibiotic, and not giving
preference to cheaper one. Keep in mind that Bulgaria is
one of the countries with the lowest GDP in Europe, and
as such the funds for health-care are smaller. Another, not
completely achieved aim is the very early start of
appropriate therapy for severe systemic infections.
In practice, antibiotic stewardship is not easily
achieved. It requires stricter infection control, improved
regulation, increased investment, and support from the
government and international organizations.
Acknowledgments. The author thanks G. Georgiev, M. Popova, G.
Opalchenova and G. Lazarova for helpful discussion.
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APUA Chapter Reports
Senior resource characters

Junior resource characters
Lactobacillus

Dermatophyte

Influenza

Penicillium

APUA-UK Update
Dr. Cliodna McNulty, President of APUA-United
Kingdom and her team have developed the
‗e-Bug‘ Website, a European wide antibiotic and
hygiene teaching resource for junior and senior school
children. The project not only reinforces an awareness of
the benefits of antibiotics, but also teaches prudent
antibiotic use, and how inappropriate use can have an
adverse effect on an individual's good microbes and
antibiotic resistance in the community. An article
published in Microbiology Today provides details on the
development of this website and the resources it
provides.
For 2012 the team have developed seven new online
games for students (see below) and two lesson plans for
teachers covering farm hygiene (junior schools) and
chlamydia (senior schools).
The e-Bug partnership consists of 24 countries
providing united health messages, with the resources
being translated into all EU languages and also Turkish.
In the 2011-2012 academic year there have been over

Viruses

Bacteria

Fungi

58,000 hits to the English website alone from 177
different countries and territories. The website also
receives a large number of hits from non partner
countries, for example, the Portuguese website has had
as many hits from Brazil as Portugal.
Lecky DM, Hawking MKD, McNulty CAM. e-Bug – Making Microbiology
and Hygiene Child‘s Play. Microbiology Today. 2011 May: 112-7.

APUA-Nepal Update
APUA-Nepal will be making two presentations at the
First International Conference on Infectious diseases and
Nanomedicine 2012 scheduled for December 15-18,
2012 in Kathmandu, Nepal. The topics of the
presentation are ―Common Isolates and their
Antibiogram in T.U Teaching Hospital (TUTH), a
tertiary care hospital in Nepal‖ and ―Efforts of APUANepal in Reducing the Emergence and Spread of
Resistance.‖
APUA-Australia
APUA-Australia will be hosting its annual meeting
―Antimicrobials 2013‖ from February 21 to 23, 2013 in
Sydney, Australia. Dr. Peter Davey, University of

New Games in 2012
Soapy Soakers: Be a microbe buster on the skin! (Hand hygiene)
Bogey Bus: What‘s the best way to stop germs spreading in a sneeze (Respiratory Hygiene)
Chicken Surprise: How safe is the food you cook? (Food Hygiene)
Doctor Doctor!: Can you treat the patient before the time runs out! (AMR)
Mixed-up Microbes: There are three types of microbes, but do you know which is which?
Happy Holidays: Get your holiday vaccine before the holiday viruses get you (Vaccinations)
Body Busters: Kill the body bugs before they get you. Remember – antibiotics don‘t kill viruses!
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Dundee in Scotland will be presenting the plenary
―Antimicrobials Stewardship‖, and Drs. Louis Rice,
Brown University and Fred Tenover, Cepheid in the
USA will be presenting ―Rapid Diagnostics and
Appropriate Antibiotic Use‖ and ―Molecular Diagnostics
for Infectious Diseases: From DNA Probes to Whole
Genome Sequencing, An Insider‘s Perspective‖
respectively. Dr. Matthew Cooper from the University of
Queensland will be presenting the plenary ―New
Antimicrobial Discovery: Promise versus Reality?‖
APUA-Georgia Update
APUA-Georgia was established in 2003 and
managed by Professor Alexander Nanuashvili until his
death in October 2011. His wife, Dr. Tamar Davitashvili
has since assumed leadership of the chapter.
In 2009, Prof. A. Nanuashvili published the volume
"Bacterial Infections", which has been of paramount
importance for Georgian physicians and microbiologists.
Through 2010-2011, before his severe illness, Prof.
Nanuashvili conducted many seminars for Georgian
doctors in the field of prudent use of antibiotics. In 2010,
Prof. Nanuashvili headed the creation of the country‘s
monitoring system and
associated data bases of
antimicrobial resistance. In the same year, APUAGeorgia conducted a national conference on antibiotic
resistance in order to review the data gathered for the
antibiotic resistance monitoring system.
Prof. Nanuashvili‘s final work "Antimicrobial
Agents‖, will shortly be published in the form of a
periodical newsletter for circulation among doctors.
Since 2011, APUA- Georgia has been taking part in the
Study for Monitoring Antimicrobial Resistance
Trends (SMART) being conducted by the International
Health Management Associates, Inc (IHMA) to monitor
worldwide antimicrobial resistance trends among aerobic
and facultatively anaerobic Gram-negative bacilli (GNB)
isolated from intra-abdominal infections.
In 2012, APUA-Georgia has been conducting
seminars for doctors on topics related to antibacterial
therapy. Soon, they plan to analyze the data collected by
the national resistance monitoring system.

Attendees of the Symposium held for establishment of APUAMayabeque sub-chapter. APUA-Cuba has created sub-chapters
in 9 out of Cuba‘s 16 provinces.

APUA-Cuba Update
APUA-Cuba continues to grow, with more than 1,400
members in over 60 medical specialties. Dr. Moisés
Morejón (Manual Fajardo Hospital) and his colleagues
have held multiple symposia on antimicrobial resistance
and the need for new antibiotics. One of its recent
conferences discussed the applicability of modern
diagnostic technology in detecting HAI pathogens and
identifying resistant phenotypes in immunocompromised
patients.
APUA-Cuba has proposed national guidelines, citing
APUA recommendations for correct antibiotic use in
critical-care patients in the face of rising rates of HAIs
and infection from multidrug-resistant Acinetobacter
baumannii. Other proposed guidelines include those for
antibiotic use in surgical prophylaxis, and parameters for
sequential antibiotic therapies that will hopefully evolve
into sophisticated antibiotic stewardship programs.
Pneumonia is another growing concern in Cuba,
especially in children, and has stimulated discussions on
the importance of correct diagnosis and provided an
incentive for pneumococcal vaccine development. APUA
-Cuba has evaluated international guidelines for
community-acquired pneumonia, citing guidelines from
IDSA/ATS and the South American working groups
ConsenSur and SEPAR as being the most useful.
This year Dr. Morejón published Enfermedades
Tropicales Mayores: Enfermedades Olvidadas o
Desatendidas (Forgotten & Neglected Tropical
Diseases).

The APUA Newsletter Vol. 30. No. 2 • © 2012 APUA

APUA Leadership Award 2012
Professor Roman S. Kozlov, M.D., M. Sc., D.Sc.
And APUA-Russia
The Alliance for the Prudent Use of Antibiotics (APUA) is pleased to present the 2012
APUA Leadership Award to Professor Roman S. Kozlov and APUA-Russia for sustained
leadership to contain antibiotic resistance in Russia and the adjacent region. This award also
recognizes the Chapter‘s collaborative efforts with the Inter-Regional Association for
Clinical Microbiology & Antimicrobial Chemotherapy (IACMAC) and the Institute of
Antimicrobial Chemotherapy (IAC) of Smolensk State Medical Academy (SSMA).
As President of APUA-Russia, Professor Kozlov has led the remarkable efforts of this
chapter to promote the prudent use of antibiotics. APUA-Russia has been extensively
involved in activities throughout Russia, Belarus, Ukraine, and other countries of the Former
Soviet Union for the establishment of a network of sentinel laboratories and organization of
continuous surveillance programs of both community and hospital-acquired pathogens.
APUA-Russia is based at SSMA in Smolensk, where Professor Kozlov serves as IAC
Director. Collaboration with the IAC has provided the laboratory facilities to develop the
surveillance work. The results of these studies have been used as a basis for development of
national guidelines on the management of community-acquired pneumonia, hospital-acquired
pneumonia, intra-abdominal infections, and skin and soft-tissue infections.
This year, the APUA Leadership Award recruited nominations for an outstanding young
professional who has demonstrated extraordinary leadership. Professor Kozlov was
recommended for this award by Dr. Stephen A. Lerner of Wayne State University and a
member of APUA‘s Scientific Advisory Board. Professor Kozlov assumed leadership of the
APUA-Russia chapter at a young age and has successfully brought to fruition many of the
goals first envisioned by his mentor and predecessor, Dr. Leonid Stratchounski. In his letter
of nomination, Dr. Lerner indicates,
―This award and these accomplishments stand on the vision of Dr. Leonid
Stratchounski whose untimely death in June 2005 was a grave tragedy for the
world‘s interests in antibiotics and resistance. Fortunately, part of Dr.
Stratchounski‘s vision was to identify promising young people in Smolensk
and to groom them for excellence in the field of antibiotics. The prime example
is Dr. Roman Kozlov. Dr. Kozlov became Dr. Stratchounski‘s lieutenant, and
he was successfully able to assume the leadership positions he holds today.‖
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Professor Kozlov also serves as President of IACMAC, an organization that has been a
beacon for epidemiologic, clinical and basic research on antibiotics and their appropriate
usage. The efforts of IACMAC to communicate their research to scientists and practitioners
across the expanse of the Former Soviet Union has a provided a great service to the field of
infectious disease. Notably, IACMAC has developed an interactive ‗Map of Antimicrobial
Resistance of Russia‘ available freely on the web site www.antibiotic.ru for the use of
physicians and microbiologists throughout the world. Furthermore, IACMAC has organized
an exemplary distant education course on antimicrobial therapy which has been successfully
completed by more than 600 physicians.
APUA is pleased to recognize Professor Kozlov‘s leadership and his success in
influencing the prudent use of antibiotics in Russia and the region. In offering his
congratulations Dr. Stuart B. Levy, President of APUA stated, ―Roman Kozlov represents a
class of emerging young leaders whose dedication is essential to ensure antibiotic
effectiveness. His leadership demonstrates the value of the APUA global network and its
affiliated chapters in 66 countries throughout the world.‖

While APUA's traditional ICAAC reception was not held this year, the award was
presented to Professor Kozlov at a special Leadership Award dinner at ICAAC co-hosted by
Drs. Thomas F. O‘Brien and Stephen A. Lerner of APUA. The dinner was attended by
representatives from some of corporate sponsors. We plan the traditional APUA reception at
next year's ICAAC in Denver, Colorado and will be formally recognizing Professor Kozlov
and APUA-Russia then.
For a list of previous award winners, please see the APUA website.
APUA-Russia is organizing the II Volga Region Conference on Antimicrobial Therapy in Samara,
Russia from October 11-12, 2012. The program in English can be viewed here.
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APUA Headquarters in Action
New APUA report: Expert advice for
antibiotic stewardship programs
APUA surveyed members from the APUA Scientific
Advisory Board regarding strategies for effective
implementation of antibiotic stewardship programs (ASP)
in healthcare facilities. They pointed out both technical
and perceptual challenges to successful implementation
of ASPs and some ways to overcome these
obstacles. Contributing experts were:
Thomas F. O‘Brien, M.D. (Brigham and Women‘s
Hospital)
Shira I. Doron, M.D. (Tufts Medical Center)
Philip D. Walson, M.D. (Geörg-August-Universität
School of Medicine; Clinical Therapeutics)
Alfred DeMaria, Jr., M.D. (Massachusetts
Department of Public Health)
Read the results of this survey on the APUA website.
More information on this topic is available in the
following past APUA Newsletters:
Enhancing Infection Control with Antibiotic
Stewardship (Vol.29 No.3)
Antibiotic Stewardship Gaining Traction:
Recommended Models and Resources (Vol.29 No.1)
Antibiotic Stewardship Programs: Proven Strategies
to Preserve Medicine‘s ―Magic Bullets‖ (Vol.24
No.1)
Additional resources are found on our website under
For Practitioners: Treatment Guidelines and Stewardship
APUA signs letter to the US Congress
requesting $547 million for BARDA
The letter is addressed to the House and Senate
Appropriations Committees and asks for an appropriation
of at least $547 million for Fiscal Year 2013 for the
Biomedical Advanced Research and Development
Authority (BARDA) . BARDA is intended to provide ―an
integrated, systematic approach to the advanced
development and purchase of necessary medical
countermeasures (MCMs), including vaccines, biological
and small molecule therapeutics, antiviral drugs,
antifungal drugs, and antibiotics, diagnostics, respiratory

devices, and other medical supplies.‖ Although the
program has been underfunded since its inception,
investments by BARDA have resulted in the
development of new therapeutics such as a new smallpox
antiviral and vaccine for HIV patients, anthrax treatments
as well as progress toward developing new anthrax
recombinant vaccines. Since private investment in
antibiotic research and development has plummeted,
BARDA has become an important source of funding for
research and development of novel antibiotics for
treatment of multi-drug resistant pathogens.
APUA Leadership Statement advocates
strengthening FDA Draft Guidance on
antibiotic use in livestock
The FDA Draft Guidance #213 (―Recommendations
for Drug Sponsors for Voluntarily Aligning Product Use
Conditions with Guidance for Industry #209‖) asks drug
companies to voluntarily remove "growth promotion"
from the lists of FDA-approved uses on their products‘
labels and instead list disease treatment, control, or
prevention. This guidance was open for public comment
until July 12, 2012.
APUA, in partnership with PEW Charitable Trusts has
been advocating for stricter drafting and enforcement of
this guidance. APUA commented on the guidance in the
form of an organizational letter urging the FDA to make
this change in labeling practices an enforceable rule
rather than a recommendation. The letter also encouraged
the FDA to remove "disease prevention" from the list of
approved uses, because allowing it can, in practice, be
identical to allowing the use of antibiotics for "growth
promotion".
In addition, APUA developed a leadership
statement addressed to President Obama and FDA
Commissioner Hamburg. APUA reached out to
colleagues for support and this statement was signed by
21 leaders in science and medicine including 4 Nobel
Laureates and 5 ASM Presidents. Please see statement on
the following page.
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Chief Executive Officers
Stuart B. Levy, President
Thomas F. O’Brien, Vice President
Kathleen T. Young, Executive
Director
Board of Directors
Stuart B. Levy, Chairperson
Harris A. Berman
Gordon W. Grundy
Bonnie Marshall
Thomas F. O’Brien
Arnold G. Reinhold
Stephen C. Schoenbaum
Philip D. Walson
Mary Wilson
Scientific Advisory Board
Jacques F. Acar, France
Werner Arber, Switzerland
Fernando Baquero, Spain
Michael L. Bennish, USA
Patrice Courvalin, France
Otto Cars, Sweden
Jose Ramiro Cruz, Guatemala
Iwan Darmansjah, Indonesia
Julian Davies, Canada
Paul Farmer, Haiti
Walter Gilbert, USA
Herman Goossens, Belgium
Sherwood L. Gorbach, USA
Ian M. Gould, Scotland
George Jacoby, USA
Sam Kariuki, Kenya
Ellen L. Koenig, Dominican Republic
Calvin M. Kunin, USA
Jacobo Kupersztoch, USA
Stephen A. Lerner, USA
Jay A. Levy, USA
Donald E. Low, Canada
Scott McEwen, Canada
Jos. W.M. van der Meer, The Netherlands
Richard P. Novick, USA
Iruka Okeke, USA & Nigeria
Maria Eugenia Pinto, Chile
Vidal Rodriguez-Lemoine, Venezuela
José Ignacio Santos, Mexico
Mervyn Shapiro, Israel
K. B. Sharma, India
Atef M. Shibl, Saudi Arabia
E. John Threlfall, United Kingdom
Alexander Tomasz, USA
Thelma E. Tupasi, Philippines
Anne K. Vidaver, USA
Fu Wang, China
Thomas E. Wellems, USA
Bernd Wiedemann, Germany

July 10, 2012
President Barack Obama
1600 Pennsylvania Ave. NW
Washington, DC 20500

and

The Honorable Margaret Hamburg, MD
Commissioner, Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

Dear President Obama and Commissioner Hamburg:
As recognized leaders in the U.S. scientific and medical community, we applaud the FDA’s
recent actions to promote judicious use of antibiotics in food-producing animals through
recommendations, delineated in its guidance documents. We support your guidance that antibiotics not
be used for growth promotion and feed efficiency, and that there be veterinary oversight in the
dispensing of antibiotics—particularly in feed and water, where whole herds and flocks are the recipients.
These voluntary guidances represent a significant shift in U.S. public health protection, as they begin to
address the high risks that non-judicious use of antimicrobials in animals pose for human health – in the
form of increases in drug resistance and potential treatment failures. We are concerned, however, that
they are insufficient and that stronger regulation is needed.
There is no reason to expect compliance from agribusiness, in view of its long history of
rebuffing regulatory efforts to curb antibiotic use. In addition, FDA considers use of antibiotics for
disease prevention to be a therapeutic use, essential to animal health. Since many drugs that have been
approved for growth promotion purposes have also been approved for routine disease prevention, we
are concerned that industry will not reduce overall antibiotic use, but merely shift from growth
promotion to prevention. We request that FDA address antibiotics used for prevention and recommend
and provide incentives for using alternative strategies, such as vaccines, probiotics, and improved
management practices, for disease prevention and control. We suggest that further guidance clearly
describe plans for monitoring progress. Specifically, the further development of our national
antimicrobial resistance monitoring system to include more geographic representation and speciesspecific data on resistance and antimicrobial use in animals and humans would go a long way to inform
and evaluate practitioner compliance and outcomes.
According to the U.S. CDC and WHO, antimicrobial resistance is one of the top five public
health threats. What is needed is an overall reduction in antimicrobial use, achieved by offering
economic incentives to adopting alternatives in conjunction with further regulatory and legislative action.
We strongly support the passage of the Preservation of Antibiotics for Medical Treatment Act (PAMTA,
H.R. 1549, S.619), which would withdraw the use of seven classes of antibiotics that are critically
important to human health from food animal production, unless specific disease conditions apply. Now
is the time to act. Thank you for your consideration.
Sincerely yours,

Stuart Levy, MD

Carol Greider, PhD

Gerald T. Keusch, MD

Francisco J. Ayala, PhD

James Hughes, MD

Professor, Former Director
Fogarty Center, NIH

Richard Novick, MD

AAAS** President

Professor, Immediate PastPresident, IDSA***

Calvin Kunin, MD, MACP

Emeritus Professor of Medicine 1997 Nobel Laureate

Stanley Prusiner, MD

2007 Nobel Laureate

George Jacoby, MD

Stephen A. Lerner, MD

Moselio Schaechter , PhD

Julian Davies, PhD

Head, Infectious Disease,
Lahey Clinic

Professor of Medicine

ASM Past President

Jay Levy, MD

Thomas Schmidt, PhD

ASM* Past President

Mario Capecchi, PhD
ASM Past President

Walter Gilbert, PhD
1980 Nobel Laureate

Michael S. Gilmore, PhD
Sir William Osler Professor

2009 Nobel Laureate

Molly Jahn, PhD

Professor, Head of Laboratory,
Professor, former Deputy Under AAAS & AAM**** Fellow
Secretary for USDA
Jeff F. Miller, PhD
Michael Katz, MD
ASM President
Professor Emeritus

Professor of Microbiology and
Medicine

2011 President Elect ASM

Alexander Tomasz, PhD
Professor, Head of Rockefeller
Laboratory
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News and Publications of Note
HIVMA
and
IDSA
Update
Policy
Recommendations for HIV
In conjunction with the July 2012 International AIDS
Conference, the Infectious Disease Society of America‘s
(IDSA) Center for Global Health Policy and HIV
Medicine Association (HIVMA) featured the 2012 HIV
compendium, Clinical Issues in HIV Medicine, and
updated policy recommendations (PDF) following the
HPTN 052 study, the first large‐scale, randomized
controlled trial showing that antiretroviral therapy
reduces the risk of sexual transmission of HIV to an
uninfected partner.
IDSA Updates Group A Strep Treatment
An update to the 2002 clinical practice guideline for
the diagnosis and management of group A streptococcal
pharyngitis was made by the Infectious Diseases Society
of America in September 2012 (see Clinical Infectious
Diseases).
In order to deter inappropriate use of antibiotics, the
guideline advises that once a strep infection is confirmed
by testing, penicillin or amoxicillin, not cephalosporin
should be used as first-line therapy. The IDSA also
recommends that children who suffer recurrent strep
throat should not have their tonsils surgically removed
solely to reduce the frequency of infection.
A podcast with the lead author has been developed
and other tools, such as mobile device and pocket-card
formats for use at the point of care, are in development
(see IDSA: practice guidelines section).
CDC Updates STD Guidelines
According to the new guidelines published in the
Center of Disease Control and Prevention‘s Morbidity
and Mortality Weekly Report in August 2012, oral
cephalosporins are no longer recommended for gonorrhea
treatment. The rationale for this change is provided by
recent data from CDC's Gonococcal Isolate Surveillance
Project that demonstrate a significant increase (17-fold

from 2006 to 2011) in the percentage of Neisseria
gonorrhoeae isolates showing tendency for cefixime
resistance. CDC recommends that doctors immediately
stop routine use of cefixime. In order to preserve the last
remaining antibiotic considered highly effective for
gonorrhea treatment,
combination therapy with
intramuscular ceftriaxone, plus either oral azithromycin
or doxycycline, is now recommended for uncomplicated
cases. If ceftriaxone is not used due to complications, a
test of cure is recommended one week after treatment.
Since cefixime and ceftriaxone are in the same class
of antibiotics, it is only a matter of time before the fastmutating N. gonorrhoeae develop resistance to
cephalosporin as well. Although there are no documented
treatment failures in the United States, untreatable
gonorrhea has already been reported in Asia and Europe.
In case of treatment failure under current guidelines, the
CDC should be notified within 24 hours. A specimen
should be collected for culture and sensitivity, and the
patient should be re-treated. The patient‘s recent partners
should also be treated.
Tufts Studies Novel Storage Medium for
Antibiotics and Vaccines
Conventional methods of antibiotic and vaccine
storage depend on refrigeration to maintain their potency.
In resource-poor settings, however, cold storage is not
always available. For example, after six months at 25°C,
conventionally freeze-dried MMR (measles, mumps,
rubella) vaccine retains only 60-75% of its potency, and
becomes virtually useless at 45° C.
Dr. David Kaplan and his team have described a new
technique for packing antibiotics and vaccines (July issue
of the Proceedings of the National Academy of Sciences)
that involves boiling silk cocoons in sodium carbonate to
extract silk fibroin. The fibroin is then treated with salt
and preservative and spread out into sheets and freezedried. With this new silk sheet packing, the MMR
vaccine retains about 85% of it‘s potency after six
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months, regardless of temperature. Similar results were
seen with tetracycline, and penicillin. Vaccines and
antibiotics stored in this silk fibroin matrix are yet to be
tested in humans, but the risk of adverse effects is
minimal given that silk, often used in sutures, is harmless
to people.
CDDEP’s Visualization Series Focuses on
Two Antibiotic Resistance Topics
The Center for Disease Dynamics, Economics and
Policy website hosts a visualization series that examines
correlations between outpatient prescribing rates of oral
vancomycin and C. difficile mortality in the United
States. The strength of the relationship suggests that drug
utilization data can be a cost-effective tool for disease
surveillance.
Another item in this visualization series focuses on the
alarming increase in retail sales of carbapenem antibiotics
in India and Pakistan. Without the enforcement of strict
regulation curbing over the counter sales, there is a grave
risk that resistant organisms will emerge and become
almost impossible to treat.
New UN Reports highlight progress on
child survival
The UN Inter-agency Group for Child Mortality
Estimation (UN-IGME) has released new data showing
that the reduction in the pace of child deaths has
accelerated sharply since 2000. Similar trends are noted
in the UNICEF‘s Report: Committing to Child Survival:
A Promise Renewed – Progress Report 2012, which
summarizes mortality estimates along with the top killers
of children under five, and outlines the practical
strategies that are needed to accelerate progress. Indeed,
progress has been made over the last two decades—thanks to sound strategies, adequate resources and, above
all, political will.
Bringing diagnostics to resource-poor
settings
Utilizing a fictitious but dramatic case-in-point
example, Michael Ingerson-Mahar brings to life the dire
scenarios of real-life people whose lack of access to point
-of-care diagnostic tests (POCTs) in the developing world

29

can mean the difference between life and death (Microbe,
Sept 2012). In Sept 2011, the American Academy of
Mi cr obi ol ogy ( AAM ) convened a panel
of microbiologists, engineers, epidemiologists and public
health officials to consider questions surrounding the
myriad, complex steps involved in the design and
development of POCTs. Their report, "Bringing the Lab
to the Patient: Developing Point-of-Care Diagnostics for
Resource Limited Settings" discusses the impacts that
POCTs could have on clinical decision-making and
highlights the need for interactive discourse between the
many players who must collaborate effectively to bring
promising POCTs to remote areas. Many obstacles must
be surmounted to achieve the ideal qualities of a POCT
for these sites: i.e., affordable, sensitive, specific, userfriendly, robust and rapid (ASSURED), as well as
integration into the larger health care system. Matching
the needs of decision-makers at resource poor locations
with the new technologies that are emanating from the
research community is a current challenge. Deficits in
communications channels that exist between the two,
coupled with regulation and licensing issues, present
enormous hurdles to overcome. Efforts spearheaded by
the journal Lab on a Chip and the Foundation for
Innovative New Diagnostics (FIND), for example, are
making progress towards filling these gaps.
CDC Funds Help Prevent HAIs
The Affordable Care Act has allowed funding of
infrastructure to implement state-based health careassociated infection (HAI) prevention programs. Sixteen
states are receiving funds for building multi-facility
prevention initiatives. Previous investments have resulted
in saved lives and health care costs in 21 states,
demonstrating significant reductions in HAIs. Four states
will receive funding for advancing the national
implementation of electronic laboratory records. The
funds will improve capacity to receive, validate, process,
and use incoming electronic laboratory records messages
in surveillance systems and ensure timely reporting of
health care-associated infections to CDC‘s National
Healthcare Safety Network.

The APUA Newsletter Vol. 30. No. 2 • © 2012 APUA

30

Upcoming Events
September 29- October 4, 2012: ASM's 6th Conference on Biofilms in Miami, FL.
October 11-12, 2012: The Interregional Association for Clinical Microbiology and Antimicrobial
Chemotherapy's II Volga Region Conference on Antimicrobial Therapyin Samara, Russia.
October 17-21, 2012: IDSA's inaugural IDWeek will be held in San Diego, CA. IDWeek is the firstever combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare
Epidemiologyof America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious
Diseases Society (PIDS). The theme of this year’s meeting is “Advancing Science, Improving Care” and
will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and
epidemiology of infectious diseases, including HIV, across the lifespan.
October 22-26, 2012: ASM's 4th Conference on Beneficial Microbes in San Antonio, TX.
October 27-31, 2012: APHA's 140th Annual Meeting and Expo will be held in San Francisco, CA on
the topic of "Prevention and Wellness Across the Life Span." The APHA meeting attracts more than
13,000 national and international physicians, administrators, nurses, educators, researchers,
epidemiologists, and related health specialists to address current and emerging issues in health science,
policy, and practice.
November 12-18, 2012: CDC's Get Smart About Antibiotics Week.
November 27-28, 2012: World Animal Health Congeress in Kansas City, MO.
February 4-8, 2013: Tufts CSDD “Postgraduate Course in Clinical Pharmacology, Drug Development
and Regulation” in Boston, MA.
February 21-23, 2013: Australian Society for Antimicrobial's Annual meeting “Antimicrobials 2013”
in Sydney, Australia.
March 14, 2013: British Soceity for Antimicrobial Chemotherapy's Spring Meeting 2013 in London, UK.

The Alliance for the Prudent Use of Antibiotics
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About Us
Antibiotics are humanity's key defense against disease-causing microbes. The growing prevalence of antibiotic
resistance threatens a future where these drugs can no longer cure infections and killer epidemics run rampant. The Alliance for the Prudent Use of Antibiotics (APUA) has been the leading global non-governmental
organization fighting to preserve the effectiveness of antimicrobial drugs since 1981. With affiliated chapters
in more than 66 countries, including 33 in the developing world, we conduct research, education and advocacy programs to control antibiotic resistance and ensure access to effective antibiotics for current and future generations.
Our global network of infectious disease experts supports country-based activities to control and monitor
antibiotic resistance tailored to local needs and customs. The APUA network facilitates the exchange of objective, up-to-date scientific and clinical information among scientists, health care providers, consumers and
policy makers worldwide.
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